DexCom, Inc. vs Goodyear Tire & Rubber Co — how do they compare? DexCom, Inc. trades at $90.8 (market cap $33.79B), while Goodyear Tire & Rubber Co trades at $6.11 (market cap $1.75B). The key difference: DexCom, Inc. is far larger — about 19.3× Goodyear Tire & Rubber Co's market cap, and DexCom, Inc. is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| DXCM | GT | |
|---|---|---|
Market Cap | $33.79B | $1.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $10.54 |
52-Week Low | $54.84 | $5.58 |
Enterprise Value | $33.24B | $9.11B |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
The Goodyear Tire & Rubber Company (GT) trades at $5.98, down 0.83% on the day, reflecting ongoing pressure from declining revenue and a significant net loss of $1.72 billion in 2025. Technical indicators are bearish, with moving averages signaling a downtrend, while fundamentals show a low P/E of 4.69 and P/B of 0.62, suggesting potential undervaluation despite negative profitability metrics like a -14.37% net income margin. Recent Q2 2026 earnings showed a loss of $0.61 per share, beating expectations but highlighting volume challenges.
GT presents a high-risk opportunity with its cheap valuation offset by weak earnings and cash flow volatility. Analyst sentiment is mixed, with 34.62% buy ratings, but risks include persistent volume declines, high debt, and competitive pressures. The stock's outlook hinges on operational improvements and market stabilization, making it speculative for value investors.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →